ArticleCancer discovery2021
LKB1/
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- Physiological MplW514L expression in hematopoietic stem cell causes an essential thrombocythemia and progressive myelofibrosis.The Journal of clinical investigation · 2026Article
- Hypoxia-inducible factors contribute to venous thrombosis in a mouse model of myeloproliferative neoplasms.Blood advances · 2026Article
- Impact of germline predisposition genes to hematologic malignancies on transplant outcomes and donor selection.Frontiers in immunology · 2026Article
- Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance.Trends in pharmacological sciences · 2025Review
- Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.Blood · 2025Article
- Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia.Haematologica · 2025Review
- High Mobility Group A1 Chromatin Keys: Unlocking the Genome During MPN Progression.International journal of molecular sciences · 2025Review
- TSPAN7 Functions as an Antitumor Agent Through the STK11/AMPK/mTOR Axis in Colorectal Cancer.Canadian journal of gastroenterology & hepatology · 2025Article
- Loss of Function Mouse Models Reveal a Novel Regulatory Function for ULK1 in Myeloproliferative Neoplasms.Molecular and cellular biology · 2025Article
- RABIF promotes hepatocellular carcinoma progression through regulation of mitophagy and glycolysis.Communications biology · 2024Article
- Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.Blood advances · 2024Article
- Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy.Frontiers in genetics · 2024Review
- Identification of Novel Risk Variants of Inflammatory Factors Related to Myeloproliferative Neoplasm: A Bidirectional Mendelian Randomization Study.Global medical genetics · 2024Article
- Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency.Haematologica · 2023Article
- Smooth muscle liver kinase B1 inhibits foam cell formation and atherosclerosis via direct phosphorylation and activation of SIRT6.Cell death & disease · 2023Article
- Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.Cancers · 2023Review
- Article
- RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis.Signal transduction and targeted therapy · 2023Article
- Article
- Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 9 institutions in 2 countries.
Christian Marinaccio *Northwestern University, Chicago, Illinois.ORCID 0000-0003-1207-697X
Praveen Suraneni *Northwestern University, Chicago, Illinois.
Hamza CelikDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Andrew VolkCincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Qiang Jeremy WenSt. Jude Children's Research Hospital, Memphis, Tennessee.
Te LingSt. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-0315-2662
Marinka BulicNorthwestern University, Chicago, Illinois.ORCID 0000-0001-9924-0036
Terra LashoMayo Clinic, Rochester, Minnesota.
Richard P KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Christopher A FamulareCenter for Hematologic Malignancies, Memorial Sloan Kettering, New York, New York.
Noushin FarnoudCenter for Hematologic Malignancies, Memorial Sloan Kettering, New York, New York.
Brady SteinNorthwestern University, Chicago, Illinois.
Michael SchieberNorthwestern University, Chicago, Illinois.ORCID 0000-0001-9994-8579
Sandeep GurbuxaniUniversity of Chicago, Chicago, Illinois.
David E RootBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0001-5122-861X
Scott T YoungerBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Ronald HoffmanMt. Sinai School of Medicine, New York, New York.
Naseema GangatMayo Clinic, Rochester, Minnesota.
Panagiotis NtziachristosNorthwestern University, Chicago, Illinois.
Navdeep S ChandelNorthwestern University, Chicago, Illinois.
Ross L LevineLeukemia Service, Department of Medicine, Memorial Sloan Kettering, New York, New York.
Raajit K RampalCenter for Hematologic Malignancies, Memorial Sloan Kettering, New York, New York.ORCID 0000-0002-0355-6368
Grant A ChallenDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Ayalew TefferiMayo Clinic, Rochester, Minnesota.
John D CrispinoNorthwestern University, Chicago, Illinois. john.crispino@stjude.org.ORCID 0000-0002-8182-8306
Northwestern University · USMemorial Sloan Kettering Cancer Center · USMayo Clinic · USBroad Institute · USSt. Jude Children's Research Hospital · USWashington University in St. Louis · USCincinnati Children's Hospital Medical Center · USMount Sinai Hospital · USUniversity of Chicago · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTissue BankP01CA108671 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Ronald Hoffman · 2006 to 2026
$82.0MMitochondrial metabolism and ROS regulate cancerR35CA197532 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CHANDEL, NAVDEEP S · 2016 to 2022
$6.3MAberrant megakaryopoiesis in the myleoproliferative neoplasmsR01HL112792 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CRISPINO, JOHN D · 2013 to 2020
$3.7MFunctions of JARID2 in Normal and Neoplastic HematopoiesisR01HL147978 · NHLBI · WASHINGTON UNIVERSITY · PI CHALLEN, GRANT ANTHONY · 2019 to 2022
$1.6MIdentifying the pathways that drive progression of the MPNs to AMLR01CA237039 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CRISPINO, JOHN D · 2019 to 2021
$1.1MGenomic profiling and development of murine models of transformation of MPNsK08CA188529 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RAMPAL, RAAJIT · 2014 to 2018
$891kTherapeutic targeting of demethylation-deubiquitination axis in acute leukemiaR01CA248770 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI NTZIACHRISTOS, PANAGIOTIS · 2020 to 2021
$726kThe Role of CHAF1B in Maintaining Malignant Leukemia Stem CellsR00CA230314 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI VOLK, ANDREW · 2020 to 2022
$693kDevelopment of novel therapies for megakaryocytic malignanciesR50CA211534 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEN, QIANG · 2016 to 2020
$670kThe Role of CHAF1B in Maintaining Malignant Leukemia Stem CellsK99CA230314 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI VOLK, ANDREW · 2019 to 2019
$104kNCI NIH HHS K08 CA188529NCI NIH HHS K99 CA230314NCI NIH HHS P01 CA108671NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA230314NCI NIH HHS R01 CA237039NCI NIH HHS R01 CA248770NCI NIH HHS R35 CA197532NCI NIH HHS R50 CA211534NHLBI NIH HHS R01 HL112792NHLBI NIH HHS R01 HL147978
Abstract
The myeloproliferative neoplasms (MPN) frequently progress to blast phase disease, an aggressive form of acute myeloid leukemia. To identify genes that suppress disease progression, we performed a focused CRISPR/Cas9 screen and discovered that depletion of LKB1/
Indexed as
Genes, Tumor SuppressorAMP-Activated Protein KinasesAnimalsDisease Models, AnimalDisease ProgressionLeukemia, Myeloid, AcuteMiceMice, Inbred C57BLMutationMyeloproliferative DisordersAMP-Activated Protein KinasesStk11 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.